Synopsis
This page is a test page for a website update. Please do NOT register for this event. Thank you.
The last decade has seen the rapid development of Late-stage functionalisation as a powerful method for enabling rapid SAR generation from a lead structure and allowing access to complex structures, biological probes and new chemical space where de-novo synthesis is not trivial. Both the inorganic catalyst and biocatalysis fields have seen new advancements over the last few years with the search for more efficient, selective, functional group tolerant, predictable methodology and new late stage transformations still a key focus. Not only are LSF methods of use in rapid SAR generation but are also finding great utility throughout the pharmaceutical industry, from metabolic identification to scale-up processes. The purpose of this meeting is to highlight some of the hot and emerging developments in the inorganic catalysis and biocatalysis arenas and both the academic and application of Late-stage functionalisation methodologies.
Attendees
This meeting is aimed at industrial and academic members of the scientific community working in pharmaceuticals, medicinal chemistry, biochemistry, biotechnology, chemical biology or broadly interested in synthesis, catalysis and enzymatic reactions. The programme will be of interest to academics, postgraduates, undergraduates and early to late career industrialists across CRO’s, SME’s and large organisations.
Programme
Tuesday 18 February
- 10.00
- Registration and refreshments
- 10.45
- Welcome and introduction
- 10.50
- Biocatalysis Plenary: How enzyme engineering enables design of
biocatalysts suitable for industrial applications
Prof. Uwe Bornscheuer, Greifwald, Germany
- 11.50
- Refreshment break, exhibition and posters
- 12.10
- GenoChemetics: Tools and Opportunities, C-H Activation Enabled in Living Cells
Prof. Rebecca Goss, St Andrews, UK
- 13.00
- Lunch and exhibition and posters
- 14.00
- Technologies and Automation in LSF: Exploring Chemical Space in Medicinal Chemistry
Dr Cara Brocklehurst, Novartis, Switzerland
- 14.50
- Methods for the activation of aromatic and aliphatic C-H bonds
Andrew Spencer, University of Manchester, UK
- 15.15
- Unconventional radicals for late stage functionalization in drug discovery
Dr Antonio Misale; Johnson and Johnson, Spain
- 15:40
- Refreshment break exhibition and posters
- 16.00
- Biocatalysis in Hit Discovery
Dr Martin Hayes, Astra Zeneca, Sweden
- 16.50
- C-H activation for late-stage peptide diversification
Prof. Lutz Ackermann, Georg-August-Universitat Göttingen, Germany
- 17:40
- Closing remarks
- 17.45
- Networking reception
Wednesday 19 February
- 08.30
- Refreshments
- 08.50
- Opening Remarks
- 09.00
- Chemistry Plenary: Catalytic Regioselective Functionalization of C-H
Bonds
Prof. John Hartwig, Berkley, USA
- 10.00
- Refreshment break exhibition and posters
- 10.20
- S,O-Ligand promoted Pd-catalyzed C-H olefination of aromatic
compounds
Prof. Tati Fernández-Ibáñez, University of Amsterdam, Holland
- 11.10
- Integration of biocatalysis into medicinal chemistry programs for late-stage oxidation using PolyCYPs enzymes
Dr Julia Shanu-Wilson, Hypha Discovery, UK
- 11.40
- Buchwald Hartwig Diversification of Unprotected Halotryptophans, Halotryptophan Containing Tripeptides and the Natural Product Barettin in Aqueous Conditions
Dr Rosemary Lynch, University of St Andrews, UK
- 12.05
- Lunch exhibition and posters
- 13.00
- Integration of electrosynthesis and biocatalysis in batch and flow
Dr Itziar Penafiel, University of Manchester, UK
- 13.25
- Photochemistry for Late-Stage Functionalization: Speeding up Lead Optimization in Drug Discovery
Dr Patricia Fernández, Sanofi-Aventis Deutschland GmbH
- 13.50
- Selective Halogenation using Mined and Engineered Halogenases
Prof. Jared Lewis. University of Indiana, USA
- 14.40
- Refreshment break exhibition and posters
- 15.00
- Late-stage Functionalization
Prof. Tobias Ritter, Harvard, USA/Max-Plank institute, Germany
- 15.50
- Closing remarks
- 16.10
- Close
Venue and Contact
Fees
Early bird fees before Friday 13 December 2019
£230 |
|
SCI Member |
£80 |
|
SCI Student Member |
£300 |
|
Non-Member |
Standard fees after Friday 13 December 2019
£360 |
|
SCI Member |
£100 |
|
SCI Student Member |
£430 |
|
Non-Member |
Student Bursaries
A limited number of student bursaries are available to registered participants, as a contribution to the cost of registration fees, travel and accommodation. The closing date for applications is 13 December 2019, to receive an application form please email conferences@soci.org.
Become an SCI Member and save on this and future events
See Membership Options
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
Booking terms and conditions
Accommodation
SCI have obtained special hotel rates for this conference. If you require hotel accommodation for the conference and would like to use SCI's special hotel rates please book your hotel room by clicking
here.
Exhibition and Sponsorship
An exhibition will take place alongside the conference for companies and related organisations who may wish to exhibit. Please email conferences@soci.org for further information and prices. Spaces are limited and will be allocated on a first-come, first-served basis.
Call for papers
Contributions are invited from those working in all areas of late stage functionalisation and biotransformations in academia and industry.
There are two options:
An abstract of maximum one A4 page or 300 words indicating title, authors and preference for presentation option (Oral or Poster) should be sent to conferences@soci.org by Friday 13 December 2019 with the subject line "LSF 2020 – abstract submission". Oral presentation slots are inevitably limited and will be allocated to achieve a balanced programme. Topics may be results, reviews or plans and may have already been presented elsewhere. Prizes will be awarded for the best poster.
Organising Committee
- Brian Cox, University of Sussex
- Chris Davis, SCI / Vertex
- Liz Jones, SCI / Syngenta
- Igor Larrosa, SCI / University of Manchester
- Martin Lowe, SCI / UCB
- Tom Pesnot, SCI / Concept life sciences
- Nick Turner, University of Manchester
- Francis Wilson, Summit Therapeutics